H. Lundbeck (HLUN A) Stock Overview
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
HLUN A Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
H. Lundbeck A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 37.00 |
| 52 Week High | DKK 40.50 |
| 52 Week Low | DKK 23.30 |
| Beta | 0.38 |
| 1 Month Change | 9.63% |
| 3 Month Change | 22.52% |
| 1 Year Change | -2.37% |
| 3 Year Change | 61.29% |
| 5 Year Change | n/a |
| Change since IPO | 17.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLUN A | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | 6.3% | 8.4% | 5.1% |
| 1Y | -2.4% | -49.9% | -31.8% |
Return vs Industry: HLUN A exceeded the Danish Pharmaceuticals industry which returned -49.9% over the past year.
Return vs Market: HLUN A exceeded the Danish Market which returned -31.8% over the past year.
Price Volatility
| HLUN A volatility | |
|---|---|
| HLUN A Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 7.9% |
| 10% least volatile stocks in DK Market | 2.4% |
Stable Share Price: HLUN A has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: HLUN A's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 5,700 | Charl van Zyl | www.lundbeck.com |
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis.
H. Lundbeck A/S Fundamentals Summary
| HLUN A fundamental statistics | |
|---|---|
| Market cap | DKK 43.57b |
| Earnings (TTM) | DKK 3.49b |
| Revenue (TTM) | DKK 23.52b |
Is HLUN A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLUN A income statement (TTM) | |
|---|---|
| Revenue | DKK 23.52b |
| Cost of Revenue | DKK 4.34b |
| Gross Profit | DKK 19.18b |
| Other Expenses | DKK 15.70b |
| Earnings | DKK 3.49b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 12, 2025
| Earnings per share (EPS) | 3.52 |
| Gross Margin | 81.55% |
| Net Profit Margin | 14.82% |
| Debt/Equity Ratio | 54.5% |
How did HLUN A perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 04:04 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
H. Lundbeck A/S is covered by 44 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| null null | ABG Sundal Collier |
| Kamla Singh | AlphaValue |